{'fraction_non_alphanumeric': 0.0327970297029703, 'fraction_numerical': 0.027227722772277228, 'mean_word_length': 5.5465587044534415, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone.

The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia added myeloid or lymphoid neoplasms with PCM1-JAK2 as provisional entities. The t(8;9)(p22;p24.1) translocation was first described in a patient in 1990, and this cytogenetic abnormality was subsequently found to result in a PCM1-JAK2 fusion gene in 2005. Approximately 50 patients with lymphoid or myeloid neoplasms associated with t(8;9)(p22;p24.1) PCM1-JAK2 have been reported, and these neoplasms have had an array of presenting diagnoses. Common features associated with this translocation are a male predominance, hepatosplenomegaly, and eosinophilia. Diagnoses reported include Philadelphia chromosome–negative myeloproliferative neoplasms, myelodysplastic or myeloproliferative neoplasms, B-cell lymphoblastic leukemia, and rarely, T-cell lymphoma. One of the initial reports in the literature describing the t(8;9)(p22; p24) translocation was found in the cutaneous T-cell lymphoma of a patient who initially was reported to have lymphomatoid papulosis, followed by a diagnosis of Hodgkin disease, with evidence that all three of these diseases were derived from a common T-cell clone. Here, we report what we believe is the second patient harboring the PCM1-JAK2 fusion with a history of cutaneous T-cell lymphoma who was later diagnosed with classic Hodgkin lymphoma. Additional immunophenotypic and molecular studies indicate that these are not two separate diseases but different manifestations of the same disease.